Navigation Links
Vigabatrin in Medical News

Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction

- Study Demonstrates Statistically Significant Efficacy vs. Placebo - - Trial Conducted Under Direction of New York University School of Medicine - CORAL GABLES, Fla., Dec. 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), a...

Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results

... license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive di...in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food &...

Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Taurine: Key to the visual toxicity of an anti-epileptic drug for children?

... vigabatrin (Sabril), first intention molecule for the treatme...d strategies for limiting it. They have shown that vigabatrin provokes a marked decrease in the blood level in a...validation of an alternative treatment associating vigabatrin and taurine, this will necessitate several years o...

Controversial medication may decrease spasms for infants with epilepsy

...Finland February 02, 2009 The antiepileptic drug vigabatrin (VGB) has been shown to be one of the best treatme...and produces more reliable results in children. vigabatrin treatment began at a mean age of 7.6 months, and t...ents. "Our results may encourage doctors to use vigabatrin to treat infantile spasms as the risk for visual f...

Hope for treating relapse to methamphetamine abuse

...(DOE) Brookhaven National Laboratory suggests that vigabatrin (a.k.a. gamma vinyl-GABA, or GVG) blocks drug-seek...nvironment. Specifically, animals pre-treated with vigabatrin lost interest in spending time in a location where...he research team. "This animal study suggests that vigabatrin could potentially prevent human methamphetamine ad...

Diet may eliminate spasms for infants with epilepsy

...trophy, and visual field constriction. ACTH, though it is effective in 60-70 percent of cases, also costs more than $80,000 for a one-month supply and vigabatrin is not currently available in the U.S. Both drugs have about a 30-40 percent recurrence rate of spasms as well. Other therapies are not yet proven. ...

Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance

... are undertaking to stem the cycle of drug addiction through treatment with vigabatrin is continuing to garner interest in the market. We were especially pleased ...of any trial conducted so far for cocaine treatment and that treatment with vigabatrin seems especially promising, even for patients that are hardest to treat -- ...

Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results

...ghts to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This ind...
Vigabatrin in Medical Technology

Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss

CORAL GABLES, Fla., Aug 21 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today reported that animal data from a new study sponsored by scientists at the U.S. Department of Energy's Brookhaven National Laboratory appears to demonstrate that taking vigabatrin ...

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

...ished clinical and non-clinical results evaluating vigabatrin as a treatment for cocaine addiction. Catalyst ex... in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions an.... The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" ...

Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results

... far for cocaine treatment and that treatment with vigabatrin seems especially promising, even for patients that...bioequivalent to Sabril(R) Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis. In Decembe...I double-blind, placebo-controlled trial, in which vigabatrin met its primary efficacy endpoint of abstinence du...

Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction

...lyst announced positive initial top-line results from a 103-patient, investigator-initiated Phase II double-blind, placebo- controlled trial, in which vigabatrin met its primary efficacy endpoint of abstinence during the last weeks of treatment for cocaine addiction. Additional results of this study will be rep...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

...lence study demonstrating that CPP-109 (Catalyst's vigabatrin Tablets) is bioavailable and bioequivalent to Sabril Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis. These data p... pre-clinical and clinical literature on Sabril. vigabatrin has been marketed over the past decade in more tha...
Vigabatrin in Biological Technology

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

...es that operate under the NIH umbrella, for future vigabatrin addiction trials and to provide a portion of the r...domized, Double-Blind, Placebo-Controlled Trial of vigabatrin for the Treatment of Cocaine Dependence in Mexican...nd Eugene M. Laska, Ph.D. The paper suggests that vigabatrin may be effective in the treatment of cocaine addic...

Catalyst Pharmaceutical Partners Receives NASDAQ Deficiency Notice

... license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive di...in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food &...

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results

...any has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents p...

Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results

...okhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents p...

Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...
Other Tags
(Date:9/21/2014)... OH (PRWEB) September 21, 2014 C8 ... District of Ohio as the list of 20 possible ... been narrowed down to six, reports Wright & Schulte ... chosen from the almost 2500 C8 lawsuits filed that ... or testicular cancer as a result of being exposed ...
(Date:9/20/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and retailer, ... . In addition, the company has launched a special offer ... is to benefit all of its big fans. Worldwide people ... , Along with beautiful party dresses, the company also ... released its new sexy short prom outfits and purple homecoming ...
(Date:9/20/2014)... Weight Destroyer , a weight loss ... Wren that has already helped tens of thousands of ... like high blood pressure, high cholesterol, and accelerated aging ... investigative review. , “Weight Destroyer is totally turning ... showing people what is truly effective when it comes ...
(Date:9/20/2014)... September 20, 2014 The Villa Group ... del Palmar Cabo San Lucas, Villa La Estancia and ... Hurricane Odile, with plans to welcome guests back to ... of Sept. 19, all members and guests of the ... to a coordinated effort with government authorities. , ...
(Date:9/20/2014)... NY (PRWEB) September 20, 2014 Ticket ... Grande concert tickets . This popular ticket exchange is ... , The 2015 schedule of tours is beginning ... have already announced their plans to hit the road, including ... Raton, Fla., announced the “Honeymoon Tour,” which will take her ...
Breaking Medicine News(10 mins):Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Beautiful Party Dresses For Autumn Unveiled By iFitDress.com 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Villa Group Resorts in Cabo Largely Unharmed, Plan to Re-open Early October 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3
(Date:9/19/2014)... years has adapted to the arctic cold, and then you ... for you. , This is happening to the small white ... called nonylphenol, comes from the use of certain detergents, pesticides ... disruptor, but when entering the worm it has another dangerous ... in its body from cold damage. , Enchytraeus albidus ...
(Date:9/18/2014)... GSA Bulletin study uses tree rings to document ... Wash in northern New Mexico, USA. By determining burial ... investigators were able to precisely date arroyo sedimentary beds ... data with aerial imagery, LiDAR, longitudinal profiles, and repeat ... Arroyos are deep, oversized channels that have vertical or ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
Other Contents